Close menu

December 28th, 2021 | 07:15 CET

BioNTech, Pfizer, Defence Therapeutics, Valneva - The Corona year 2022 is coming

  • Biotechnology
Photo credits:

The German government has moved its goal of vaccinating 80% of the population against the coronavirus at least once into the new year. The targeted quota is now to be achieved by the end of January, a government spokesman told the press. The background is that only 73.4% of the population has been vaccinated so far, and the missing 5.3 million first-time vaccinations could hardly be achieved by January 7. The interim goal of 30 million vaccinations by the end of the year, on the other hand, will most likely be met after Christmas, government sources say. The general vaccination obligation is to come on the agenda of the Federal Parliament in the first meeting week in the new year. Thus also the year 2022 will stand under the star "Corona". The following shares are part of the orchestra.

time to read: 5 minutes | Author: André Will-Laudien
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , PFIZER INC. DL-_05 | US7170811035 , DEFENCE THERAPEUTICS INC | CA24463V1013 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:

    BioNTech and Pfizer - Anti-Corona pill or continue vaccinating?

    According to the pronouncements of most immunologists who speak publicly in the media, the virus cannot be stopped without further progress in vaccination rates. A general vaccination requirement in Germany and many other countries is being discussed, so the target for the new year 2022 is already set. BioNTech and its US partner Company Pfizer are taking a two-pronged approach, offering the well-known vaccine "Comirnaty" as well as the new drug "Paxlovid".

    The broad vaccination of the population is a clear goal of governments, but there is also initial progress on the part of drug manufacturers in the development of drugs. In this context, the question arises as to how effective Pfizer's anti-corona pill "Paxlovid" is and when it will be available? Hope germinated shortly before Christmas with the emergency approval of two drugs against the coronavirus in the USA: The combination of vaccines and drugs could herald a change in the pandemic.

    BioNTech shares have been the clear blockbuster among vaccine manufacturers since their launch in August 2019. The placement price was USD 20 - in the summer of 2021, the shares reached over USD 450. As a result, the Marburg-based Company was already valued at over USD 100 billion. Currently, the share price is coming under some pressure due to profit-taking and is hovering between USD 240 and 270. If one believes analysts' estimates, the valuation of the BioNTech share for 2022 is already at a P/E ratio of less than 10. In 2021, a return of over 160% could be achieved with the share.

    Pfizer didn't really get going until late 2021 when it was announced that the drug giant was working on a Corona medication. Now, a new oral drug has been approved and is flushing initial revenue into the Company. In the last quarter of 2021, the share price increased by over 40%. With a dividend yield of 3.8% and a P/E ratio in 2022 of 13, the stock is not expensive. Pfizer is even suitable for addition to conservative portfolios.

    Defence Therapeutics - Further progress in gene-editing technology

    Defence Therapeutics (DTC) is a publicly-traded biotech company based in Canada working to develop the next generation of vaccines and ADC products using its proprietary platform. The core of the Defence Therapeutics platform is ACCUM technology, which enables precise delivery of vaccine antigens or ADCs in the intact form to target cells. As a result, improved efficiency and efficacy against serious diseases such as cancer and infectious diseases can be achieved.

    Defence Therapeutics has now announced that the use of the Accum™ platform can effectively enhance Cas9 delivery to target cells, significantly advancing gene-editing technology. CRISPR gene editing involves the targeted replacement of gene sequences. The new technology has the potential to transform medicine by enabling the treatment or prevention of numerous diseases through targeted deletion or insertion of genes. The biotech industry has been searching for years for methods that can be used to treat numerous diseases such as cancer, viral diseases (HIV and hepatitis B), and various genetic disorders.

    The essence of this technology is simple and requires two important tools. First, a piece of genetic material to drive the editing process, and second, the delivery of a Cas protein to edit the DNA. The Accum platform is designed to enrich a specific molecule in target cells. The Defence team has tested Accum's ability to enhance the delivery of Cas9 into cells continuously. With only a single Accum dose and without the additional use of a complex lipid formulation, the results obtained are astounding. Accumulation of Accum-bound Cas9 in the nucleus was at least 9-fold higher than that of free Cas9 when added to mammalian cells in vitro. Given these impressive data, Defence will actively seek partnerships with key players in the field to advance the development of CRISPR-based treatments for specific indications.

    According to an analysis by Fior Markets, the global genetic editing market is expected to grow from USD 4.2 billion in 2020 to USD 13 billion in 2028, a weighted growth rate (CAGR) of 15.2% per annum. Defence Therapeutics is at the forefront of many human genetics topics and is advancing innovatively. The stock is still in the early stages of its development, with a market capitalization of CAD 195 million.

    Valneva - First sales of the dead vaccine have been made

    French vaccine maker Valneva is gearing up to shake up the vaccine market in a big way next year. With orders slowly taking shape and becoming substantial, the Company is currently negotiating with the Scottish authorities for a grant to build another production facility. A modern production line for the VLA2001 vaccine is to be built in Livingston. A government grant of 10 to 20 million pounds is being considered to create new capacities and jobs. Valneva will urgently need this production facility to meet upcoming supply agreements.

    Unlike the vaccines approved in Europe from AstraZeneca, BioNTech and Johnson & Johnson, which are vector or mRNA vaccines, Valneva is developing an inactivated vaccine to fight COVID-19 and has already submitted a marketing authorization application to the EMA in Amsterdam. With approval, the Company will have access to many people who have refused vaccination with the new, little-researched mRNA vaccines but who do not oppose vaccination in the traditional way.

    The German government has also already ordered 11 million doses of the vaccine, and negotiations are currently underway with several countries about possible deliveries. The Valneva share is currently riding a roller coaster on the stock market, as the pending approval is decisive for the success of the vaccine producer. The price is currently fluctuating, very volatile, between EUR 23 and 27. However, with a 12-month price performance of 230%, the Valneva share is already the clear winner among listed vaccine producers. Next year, things should continue positively if everything goes smoothly with the approval. At the moment, the share is only suitable for speculative investors, but one should always keep an eye on the news ticker.

    The biotech companies presented here are subject to different cycles. BioNTech and Pfizer are already established companies with approved products. Valneva could become the next shooting star with an approval. Defence Therapeutics is very variably positioned with its platform and can deliver surprises at any time.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET

    Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics

    • Biotechnology
    • Pharma

    Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.


    Commented by Armin Schulz on November 29th, 2023 | 06:30 CET

    MorphoSys, Cardiol Therapeutics, Bayer - Where will the rebound start first?

    • Biotechnology
    • Pharma

    2023 was a challenging year for pharmaceutical and biotech companies. After the boom years of the Corona pandemic, many companies went into a tailspin. But not just vaccine manufacturers were hit; others were dragged down too. The markets are currently volatile. MorphoSys has seen a peak gain of 145% since the beginning of the year - but is currently only up 35%. Cardiol Therapeutics has also gained over 140% and has recently consolidated. The share is currently up 74% since the beginning of the year. Only Bayer's performance curve is pointing downwards. The share is currently worth 34% less than on January 2. We look at where the rebound will start first after the consolidations.


    Commented by Fabian Lorenz on November 23rd, 2023 | 07:40 CET

    Buy now? Morphosys, Siemens Energy and Desert Gold share

    • Mining
    • Gold
    • renewableenergies
    • Biotechnology

    What do renewable energies, biotech and gold have in common? Shares from these sectors have predominantly experienced significant losses in 2023. Morphosys, Siemens Energy and Desert Gold are examples of this. However, the underperformers in the current year are often among the top performers in the upcoming year. Can this apply to these three shares? In the case of Morphosys, the latest study data has been confusing, and the share has given back its gains of the year. Analysts are now expressing their views. Siemens Energy has lost over 30% of its value due to operational problems, and the price targets of the experts vary widely. Explorer Desert Gold has been quiet recently. Is it the calm before a price jump? In any case, the share is anything but expensive.